A new clinical trial is moving forward in the United States to study a potential treatment for Duchenne muscular dystrophy (DMD), a condition that causes progressive muscle weakness, mainly in boys.
The U.S. Food and Drug Administration (FDA) has approved a study of a therapy called Ryoncil (remestemcel-L-rknd), developed by Mesoblast. This treatment is already approved for another serious childhood condition and has shown a strong safety record in children.
Unlike some therapies that focus on replacing the missing dystrophin protein in DMD, Ryoncil works by reducing inflammation in the body. Inflammation is a key factor that contributes to muscle damage in DMD. Researchers hope that by targeting inflammation, this treatment could help preserve muscle function and slow disease progression. Ryoncil is a cell-based therapy made from special donor cells known as mesenchymal stromal cells (MSCs) that help control inflammation in the body. Researchers believe that reducing this inflammation could help protect muscles, slow down disease progression, and maintain strength for longer.
The trial will include 76 children with DMD aged 5-9 years of age in the USA. Participants will receive either the treatment or a placebo, alongside standard care, over a 9-month period. One of the main ways researchers will measure success is by looking at how quickly a child can stand up from the floor, which is a meaningful indicator of muscle function.
While this is still a research study and not yet a cure, it represents an important step toward new treatment options, especially those that target inflammation, an area not fully addressed by current therapies. And the hope is that trials will come to Canada.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: